Finnish medical device company Bioretec is seeking CE mark approval for its bioresorbable RemeOs trauma screw to commercialise it in the European Union region.

Part of the new RemeOs product family, the bioresorbable magnesium alloy trauma screw has been designed to fix bone fractures (osteosynthesis). It is also designed for the fixation after osteotomies.

Designed to be naturally replaced by bone, the RemeOs bioresorbable magnesium implant enables bone to heal and avoid removal operations that are needed in multiple operations while using traditional implants.

Bioretec stated that it intends to secure the CE mark and launch the bioresorbable magnesium alloy trauma screw into the markets in the European Union during this year.

The company is developing the new RemeOs product line using a magnesium alloy and hybrid composite, thereby helping to improve surgical outcomes.

Bioretec CEO Timo Lehtonen said: “Filing for the CE mark on schedule is an important milestone in the commercialization of our first RemeOs product and a great end to our first year as a listed company.

“I am proud of our team’s commitment and effort to reach this milestone. It follows our strategic goal of developing and commercialising innovations that increase patients’ quality of life.”

The RemeOs implants are resorbed and replaced by bone and help in avoiding removal surgery while facilitating fracture healing.

According to the company, the combination can make titanium implants redundant and help clinics achieve their value-based healthcare targets.

Bioretec offers its bioresorbable orthopaedic implants in around 40 countries across the globe.